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The human immunodeficiency virus (HIV) type 1 Tat protein
plays a key role in the life cycle of the virus and in patho-
genesis and is highly conserved among HIV subtypes. On
the basis of this and of safety, immunogenicity, and efficacy
findings in monkeys, Tat is being tested as a vaccine in phase
1 trials. Here, we evaluated the incidence and risk of pro-
gression to advanced HIV disease by anti-Tat serostatus in
a cohort of 252 HIV-1 seroconverters. The risk of progression
was lower in the anti-Tat–positive subjects than in the anti-
Tat–negative subjects. Progression was faster in the persis-
tently anti-Tat–negative subjects than in the transiently anti-
Tat–positive subjects, and no progression was observed in
the persistently anti-Tat–positive subjects.
Tat is a regulatory protein of HIV that is expressed very early
after infection and is essential for virus gene expression, rep-
lication, and transmission [1, 2]. Several studies have suggested
that an immune response to Tat may play a role in the control
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of HIV disease progression [3–8]. The results of preclinical
studies with anti-HIV Tat-based vaccines have supported this
concept: vaccination has been shown to be safe and to induce
specific immune responses capable of containing virus repli-
cation in monkeys and mice, and vaccination has been shown
to prevent disease after pathogenic virus challenge in monkeys
[9–11]. Moreover, Tat is highly conserved in its immunogenic
regions among all group M subtypes [12]. Recent data have
indicated cross-recognition of a clade B strain–derived (BH-10)
Tat protein by serum samples from African individuals infected
with different HIV-1 subtypes [12]. On the basis of these results,
preventive and therapeutic phase 1 clinical trials with the native
Tat protein are ongoing in Italy. In the present study, to identify
immune responses that may be predictive of HIV disease pro-
gression, we evaluated the prognostic value of anti-Tat anti-
bodies in a cohort of subjects with estimated dates of HIV-1
seroconversion both before and after introduction of highly ac-
tive antiretroviral therapy (HAART).
Subjects, materials, and methods. The study population
consisted of 252 individuals with estimated dates of HIV-1 se-
roconversion who enrolled in the Italian HIV-Seroconversion
Study at 2 participating clinical centers between 1985 and 2000.
Each subject had a negative HIV-1 test followed by a positive
HIV-1 test within 24 months, and the date of seroconversion
was estimated as the midpoint between the dates of the 2 tests
[13]. For all subjects, clinical and laboratory data—including
CD4+ T cell counts and antiretroviral-therapy status—were col-
lected every 6 months. Serum samples were collected after the
estimated date of HIV-1 seroconversion; sequential serum sam-
ples were available for 139 (55.2%) of the 252 subjects. Viral
load was determined as described elsewhere [14].
Anti-Tat IgG was detected by use of an algorithm based on 2
recently described ELISAs [12]. These validated assays were de-
veloped to obtain high levels of sensitivity and specificity using
a recombinant, purified, native Tat protein derived from the IIIB
strain (a BH-10 clone) of HIV-1 (clade B) as antigen [12].
The association between the presence of anti-Tat antibodies
and demographic and clinical parameters of the study subjects
was analyzed by use of the x2 test for categorical variables and
the Mann-Whitney U test for continuous variables. The ex-
panded AIDS case definition (category C [AIDS-defining ill-
nesses] and category 3 [CD4+ T cell count of 200 cells/mL]
of the 1993 revised classification system for HIV infection) was
used as the study end point. The incidence of events per 1000
person-years (p-y) and the 95% confidence intervals (CIs) were
calculated for the anti-Tat–positive and anti-Tat–negative sub-
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Figure 1. Kaplan-Meier curves showing progression to AIDS (cumulative incidence of AIDS or CD4+ T cell counts of 200 cells/mL [CD4+ 200]).
The cumulative incidences of AIDS or severe immunodeficiency were calculated for both the anti-Tat–positive subjects and the anti-Tat–negative
subjects; disease progression was significantly slower in the positive subjects than in the negative subjects ( , log-rank test). Anti-Tat AbpPp .016
0, subjects negative for anti-Tat antibodies; anti-Tat Ab 100, subjects with anti-Tat antibody titers 100; no. at risk, the no. of subjects who were
evaluated every 3 years, stratified by anti-Tat serostatus.
jects. The Kaplan-Meier method was applied to estimate the
cumulative probabilities of developing the end point by anti-
Tat serostatus. Event-free time was defined as the interval be-
tween the estimated date of HIV-1 seroconversion and the onset
of the event, death, or the end of the study (30 June 2001),
whichever came first. The difference between the progression
curves was assessed by use of the log-rank test. A multivariate
Cox model was used to estimate the relative hazards (RHs) of
reaching the end point for the anti-Tat–positive subjects and
the anti-Tat–negative subjects, after adjustment for age at se-
roconversion, sex, exposure category, and calendar year, which
was entered as a time-dependent dichotomous variable (Jan-
uary 1985–May 1996 vs. June 1996–June 2001). This latter
variable was used as a proxy of the effect, at a population lev-
el, of HAART, which was introduced after 1 June 1996. P val-
ues and the 95% CIs of the RHs were calculated to assess the
statistical significance of the associations. RHs were estimated
with the dates of the first anti-Tat tests included as staggered
entries (taking into account the different durations of infection
reached at the dates). The multivariate analysis was repeated
on a subset of the 139 subjects who had at least 2 consecutive
anti-Tat tests; RHs were estimated for the subjects who were
persistently anti-Tat positive (defined as those who had at least
2 positive tests) and for the subjects who were transiently anti-
Tat positive (defined as those who had only 1 positive test).
Results. The study population consisted of 252 HIV-1–pos-
itive subjects; 166 (65.9%) were men and 86 (34.1%) were
women. The median follow-up time was 7.2 years (range, 0.2–
15.8 years). The median age was 28 years (range, 17–68 years).
Injection drug use (IDU) was the most commonly reported ex-
posure category (134 subjects [53.2%]), followed by hetero-
sexual contact (63 subjects [25.0%]) and male-to-male homo-
sexual contact (51 subjects [20.2%]).
Of the 252 subjects, 30 (11.9%) were anti-Tat positive; anti-
Tat antibodies were detected at a median of 4.1 years after HIV-
1 seroconversion (range, 0.1–15.0 years). There was no statis-
tically significant difference by anti-Tat serostatus with regard
to sex ( ) or exposure category ( , for IDU vs.Pp .257 Pp .355
non-IDU); however, the anti-Tat–positive subjects were signif-
icantly younger than the anti-Tat–negative subjects (median
ages, 25 vs. 29 years, respectively; ).Pp .042
Of the 252 subjects, 95 (7 of the 30 anti-Tat–positive subjects
and 88 of the 220 anti-Tat–negative subjects) progressed to
AIDS-defining illnesses (48 subjects) or CD4+ T cell counts of
200 cells/mL (47 subjects), for an incidence of 59.5 events/
1000 p-y (95% CI, 48.7–72.8 events/1000 p-y; calculated on
the basis of 1595 p-y). Before June 1996, the proportion of
subjects who had received antiretroviral monotherapy before
developing AIDS was lower for the anti-Tat–positive subjects
( , for HAART; , for dual therapy; andPp .567 Pp .318 Pp
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Table 1. Crude and adjusted relative hazards (RHs) of AIDS or severe immunodeficiency for
anti-Tat–positive subjects vs. anti-Tat–negative subjects.
Comparison
RH (95% CI)
Crude P Adjusteda P
Anti-Tat positive vs. anti-Tat negative 0.40 (0.18–0.86) .020 0.41 (0.19–0.89) .027
Age at seroconversionb 1.09 (0.86–1.38) .478 1.13 (0.86–1.48) .577
Sex (men vs. women) 1.20 (0.77–1.87) .416 NI …
Exposure category
Man-to-man homosexual contact vs. IDU 0.83 (0.48–1.43) .500 NI …
Heterosexual contact vs. IDU 0.81 (0.48–1.37) .441 NI …
Other/unknown exposure category vs. IDU 0.00 .981 NI …
Calendar yearc 0.51 (0.32–0.80) .004 0.53 (0.34–0.83) .004
NOTE. The RHs of AIDS or severe immunodeficiency, stratified by anti-Tat serostatus, were evaluated in the
95 (of 252) subjects who reached the primary end points within the study period. CI, confidence interval; IDU,
injection drug use; NI, not included in the model.
a Adjusted for the other variables shown in the table.
b RHs estimated for increments of 10 years.
c Follow-up after June 1996 vs. follow-up before June 1996 (used as a proxy for the effect, at a population level,
of the introduction of highly active antiretroviral therapy).
, for monotherapy). After June 1996, a nonsignificantly.030
higher proportion of the anti-Tat–positive subjects had received
monotherapy ( ), dual therapy ( ), or HAARTPp .791 Pp .093
( ).Pp .932
The cumulative incidence of clinical or immunological AIDS
events 10 years after HIV seroconversion was 26.1 events/1000
p-y (95% CI, 12.3–49.9 events/1000 p-y) in the anti-Tat–positive
subjects and 53.9 events/1000 p-y (95% CI, 45.4–63.0 events/
1000 p-y) in the anti-Tat–negative subjects (figure 1), and this
lower incidence in the anti-Tat–positive subjects was statistically
significant ( , log-rank test). The median survival timesPp .016
were 12 and 9 years for the anti-Tat–positive and anti-Tat–neg-
ative subjects, respectively.
After adjustment for possible confounding variables (age at
seroconversion, sex, exposure category, and calendar year), the
RH of developing clinical or immunological AIDS for the anti-
Tat–positive subjects versus the anti-Tat–negative subjects was
0.41 (95% CI, 0.19–0.89) (table 1). When the dates of the first
anti-Tat tests were included as staggered entries in the Cox
model, the adjusted RH was 0.34 (95% CI, 0.08–1.43).
The effect of HAART was also evaluated via the calendar-year
analysis. For the comparison of the anti-Tat–positive subjects
versus the anti-Tat–negative subjects, the RHs of developing an
event (adjusted for age at seroconversion, sex, and exposure cat-
egory) were 0.20 (95% CI, 0.05–0.83) and 0.66 (95% CI, 0.25–
1.72) before and after the introduction of HAART, respectively.
A longitudinal analysis was performed on a subset of the 139
individuals who had at least 2 anti-Tat measurements (range,
2–8 anti-Tat measurements). Of these subjects, 119 (85.6%) were
persistently anti-Tat negative, 10 (7.2%) were persistently anti-
Tat positive, and 10 (7.2%) were transiently anti-Tat positive
(7 who were initially positive became negative, and 3 who were
initially negative became positive).
Overall, 53 (38.1%) of these 139 subjects experienced an
event. None of the persistently anti-Tat–positive subjects de-
veloped an event, whereas the incidences were 28.3 events/1000
p-y (95% CI, 13.5–59.3 events/1000 p-y) in the transiently anti-
Tat–positive subjects and 65.3 events/1000 p-y (95% CI, 53.0–
80.5 events/1000 p-y) in the persistently anti-Tat–negative sub-
jects. Although not statistically significant, the transiently anti-
Tat–positive subjects had a nearly 70% reduction in the risk of
progression, compared with the persistently anti-Tat–negative
subjects (crude RH, 0.31 [95% CI, 0.07–1.27] [ ]; ad-Pp .104
justed RH, 0.33 [95% CI, 0.08–1.38] [ ]). The adjustedPp .128
RHs of clinical or immunological AIDS for the transiently anti-
Tat–positive subjects versus the persistently anti-Tat–negative
subjects were 0.29 (95% CI, 0.07–1.21) and 0.42 (95% CI, 0.05–
3.35) before and after introduction of HAART, respectively.
We also investigated viral load patterns, applying a random
coefficient model. After 1996, when viral load measurements be-
came available, the decreases were 0.38 log10 copies/mL (95%
CI, 0.41 to 0.18 log10 copies/mL) per year in the persistently
anti-Tat–positive subjects and 0.27 log10 copies/mL (95% CI,
0.33 to 0.20 log10 copies/mL) per year in the persistently anti-
Tat–negative and transiently anti-Tat–positive subjects combined.
The difference between the slopes was not statistically significant.
Discussion. Previous studies have suggested that a humoral
immune response to Tat may predict slower HIV disease pro-
gression. Cross-sectional studies have shown a higher preva-
lence of anti-Tat antibodies in asymptomatic HIV-infected per-
sons than in those in advanced disease stages [3–8]. Inverse
correlations between anti-Tat humoral response and both p24
antigenemia [3, 7] and plasma viral load [4] have been de-
scribed. In addition, the presence of anti-Tat antibodies has
been shown to be more common in nonprogressors than in
fast progressors and predictive of clinical stability in nonpro-
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gressors, in both cross-sectional and longitudinal studies [11,
12]. These findings suggest that anti-Tat antibodies may rep-
resent a surrogate marker of other protective factors (e.g., cy-
totoxic T lymphocyte [CTL] response). The above-mentioned
studies, however, may have been limited by a small population
size, a short duration of follow-up, or a lack of information
on HIV seroconversion date.
The results of the present study reveal a strong association
between the presence of anti-Tat antibodies and a slower pro-
gression to clinical and immunological (AIDS-defining) end
points. After adjustment for age and calendar year (the latter
as a proxy for introduction of HAART), the anti-Tat–positive
subjects in our study had a 60% lower risk of disease pro-
gression, compared with the anti-Tat–negative subjects. The
analysis of the subjects with sequential serum samples indicated
that the persistently anti-Tat–positive subjects had the lowest
risk of disease progression, whereas the persistently anti-Tat–
negative subjects had the highest risk of disease progression.
Furthermore, the transiently anti-Tat–positive subjects had a
nearly 70% lower risk of progression, compared with the per-
sistently anti-Tat–negative subjects. These results provide evi-
dence that the presence of anti-Tat antibodies is a good pre-
dictor of slower progression of HIV disease.
Before firm conclusions can be drawn, however, the limi-
tations and biases of the present study should be mentioned.
First, whether anti-Tat antibodies are a proxy of other immune
effector mechanisms, such as specific cellular immunity or im-
mune response to other regulatory HIV proteins, remains un-
clear. Second, the anti-Tat antibody prevalence found in our
study population was lower than that found in other study
populations, which ranges from 13% in persons with prolonged
p24 antigenemia, to 29% in recently infected persons [15], and
to 100% in asymptomatic persons [3]. This phenomenon may
be due to differences in the study populations (e.g., different
disease stages) or to the lack of assay standardization and may
affect interstudy comparisons, but it is unlikely to affect esti-
mates of the strength of the association between antibody pro-
file and the risk of disease progression. Third, the lag time
between the estimated date of seroconversion and the date of
collection of the first serum sample was greater in the anti-
Tat–positive subjects than in the anti-Tat–negative subjects.
However, when the dates of collection of the first serum sample
were included as staggered entries in the survival analysis, the
magnitude of the RH of the main end point did not change
significantly. Fourth, viral load data were available since 1996
only; therefore, they should be interpreted with caution. Finally,
adjustment by age was crucial with respect to dealing with
confounding variables, because of the wide age range and the
higher prevalence of anti-Tat antibodies in the younger subjects.
In conclusion, the presence of anti-Tat antibodies is a pre-
dictor of slower HIV disease progression. The association re-
mains after adjustment for calendar year, considered as a proxy
for the introduction of HAART. The issue of whether anti-Tat
antibodies play a direct protective role or are only an indirect
marker of protection merits further investigation. Nevertheless,
in concert with the assessment of cell-mediated immunity (T
helper cells and CTLs), anti-Tat antibodies may be a valuable
tool with which to monitor the immunogenicity of Tat-based
vaccines during advanced clinical testing.
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